Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) and Tyra Biosciences (NASDAQ:TYRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.
Profitability
This table compares Checkpoint Therapeutics and Tyra Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Checkpoint Therapeutics | N/A | N/A | -659.07% |
| Tyra Biosciences | N/A | -24.56% | -23.31% |
Valuation and Earnings
This table compares Checkpoint Therapeutics and Tyra Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Checkpoint Therapeutics | $47,000.00 | 3,626.11 | -$51.85 million | ($1.84) | -1.90 |
| Tyra Biosciences | N/A | N/A | -$69.13 million | ($1.61) | -8.74 |
Volatility and Risk
Checkpoint Therapeutics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Checkpoint Therapeutics and Tyra Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Checkpoint Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Tyra Biosciences | 0 | 0 | 5 | 0 | 3.00 |
Checkpoint Therapeutics currently has a consensus price target of $13.50, indicating a potential upside of 286.82%. Tyra Biosciences has a consensus price target of $31.00, indicating a potential upside of 120.33%. Given Checkpoint Therapeutics’ higher possible upside, equities research analysts plainly believe Checkpoint Therapeutics is more favorable than Tyra Biosciences.
Institutional & Insider Ownership
22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by company insiders. Comparatively, 15.4% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Checkpoint Therapeutics beats Tyra Biosciences on 6 of the 11 factors compared between the two stocks.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
About Tyra Biosciences
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
